Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion

Nateglinide is a new, fast-onset, short-acting hypoglycemic agent, which increases early phase insulin secretion and the total amount of insulin secreted. However, it is not clear which of these effects contribute more to the decrease in postprandial plasma glucose (PG). To further clarify the pharm...

Ausführliche Beschreibung